Cancer Genetics (OTCQB: CGIX) is one of the most compelling opportunities we’ve seen in 2013. The developer of DNA-based cancer diagnostics is emerging as a leader in what looks to reshape the future of oncology care globally. With collaborations and partnerships in place with the most prestigious organizations in cancer care and the endorsement of brokerage firm Feltl & Company, who recently initiated research coverage on CGIX with a Strong Buy rating and a $17.50 price target, 2013 is setting up to be a great year for CGIX shareholders.

CGIX is an emerging leader in a field that’s transforming the way cancer is diagnosed and treated. CGIX’s tests can determine the specific genetic mutation that’s causing the cancer, enabling doctors to make more informed treatment decisions. The Company primarily focuses on hematological, urogenital, and gynecological cancers. According to the Feltl & Company report, CGIX has “an unrivaled position” in these categories. Continue reading “Why Interest is Growing in Cancer Genetics” »